AbbVie Yönetim

Yönetim kriter kontrolleri 1/4

AbbVie CEO'su Robert Michael, Jul2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 14.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.9% maaş ve 90.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.006% ine doğrudan sahiptir ve bu hisseler € 16.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 11.8 yıldır.

Anahtar bilgiler

Robert Michael

İcra Kurulu Başkanı

US$14.4m

Toplam tazminat

CEO maaş yüzdesi	9.9%
CEO görev süresi	less than a year
CEO sahipliği	0.006%
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	11.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Robert Michael'un ücretlendirmesi AbbVie'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$5b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$14m	US$1m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$10m	US$1m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$12m	US$1m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$13m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$9m	US$907k	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$3m	US$554k	US$6b

Tazminat ve Piyasa: Robert 'nin toplam tazminatı ($USD 14.44M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.78M ).

Tazminat ve Kazançlar: Robert şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Robert Michael (54 yo)

less than a year

Görev süresi

US$14,441,320

Tazminat

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 66.1m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 16.8m
Scott Reents	Executive VP & CFO	2.4yrs	US$10.19m	0.00087% € 2.6m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.011% € 34.1m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% € 10.6m
Roopal Thakkar	Executive VP of Research and Development & Chief Scientific Officer	less than a year	Veri yok	0.00092% € 2.8m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Perry Siatis	Executive VP	2.1yrs	Veri yok	0% € 0
Sanjay Narayan	Senior VP	1.1yrs	Veri yok	Veri yok
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% € 2.3m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	1.1yrs	Veri yok	Veri yok
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.8yrs	Veri yok	0.0032% € 9.5m

1.1yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 4AB 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 66.1m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 16.8m
Roxanne Austin	Lead Independent Director	11.8yrs	US$388.39k	0.00065% € 2.0m
Thomas Freyman	Independent Director	4.5yrs	US$389.98k	0.0071% € 21.3m
Glenn Tilton	Independent Director	11.8yrs	US$421.58k	0.0014% € 4.2m
Edward Rapp	Independent Director	11.8yrs	US$394.98k	0.00090% € 2.7m
William H. Burnside	Independent Director	11.8yrs	US$377.48k	0% € 0
Frederick Waddell	Independent Director	11.8yrs	US$369.98k	0.00011% € 330.3k
Melody Meyer	Independent Director	7.5yrs	US$369.98k	0% € 0
Brett Hart	Independent Director	8.8yrs	US$384.98k	0% € 0
Rebecca Roberts	Independent Director	6.5yrs	US$359.98k	Veri yok
Robert Alpern	Independent Director	11.8yrs	US$461.18k	0.000010% € 30.0k

11.8yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4AB 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.8 yıldır).

AbbVie Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Executive Chairman recently sold €11m worth of stock

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Announces Board Changes

AbbVie Inc. Announces Board of Directors Changes

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

Recent updates

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 16%

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings released: EPS: US$0.88 (vs US$1.00 in 3Q 2023)

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold €11m worth of stock

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023)

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş